Title (en)

METHODS AND COMPOSITIONS FOR TREATING HYPERTENSION, ANGINA AND OTHER DISORDERS USING OPTICALLY PURE S(-) NITRENDIPINE.

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HYPERTONIE, ANGINA UND ANDEREN ERKRANKUNGEN UNTER VERWENDUNG VON OPTISCH REINEM S(-) NITRENDIPIN.

Title (fr)

PROCEDES ET COMPOSITIONS PERMETTANT DE TRAITER L'HYPERTENSON, LES ANGINES ET D'AUTRES AFFECTIONS AU MOYEN DE NITREDIPINE S(-) OPTIQUEMENT PURE.

Publication

EP 0663822 A4 19970423 (EN)

Application

EP 93922832 A 19931005

Priority

- US 9309463 W 19931005
- US 95720092 A 19921006

Abstract (en)

[origin: WO9407476A1] Methods and compositions are disclosed utilizing the optically pure S(-) isomer of nitrendipine. This compound is a potent drug for the treament of hypertension while avoiding the concomitant liability of adverse effects associated with the administration of the racemic mixture of nitrendipine. The S(-) isomer of nitrendipine is also useful for the treatment of angina and such other conditions as may be related to the activity of S(-) nitrendipine as a calcium channel antagonist without the concomitant liability of adverse effects associated with the racemic mixture of nitrendipine.

IPC 1-7

A61K 31/04

IPC 8 full level

A61K 9/08 (2006.01); **A61K 31/44** (2006.01); **A61P 9/00** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 11/08** (2006.01); **A61P 13/02** (2006.01); **A61P 15/00** (2006.01); **A61P 25/00** (2006.01); **A61P 43/00** (2006.01); **C07D 211/90** (2006.01)

CPC (source: EP)

A61K 31/44 (2013.01); **A61P 9/00** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 11/08** (2017.12); **A61P 13/02** (2017.12); **A61P 15/00** (2017.12); **A61P 25/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

- [XD] ELTZE ET AL.: "Stereoselective Inhibition of Thromboxane-Induced Coronary Vasoconstriction by 1,4-dihydropyridine Calcium Channel Antagonists", CHIRALITY, vol. 2, no. 4, 1990, pages 233 - 240, XP000616626
- [X] MAST ET AL.: "Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.", BR. J. CLIN. PHARMAC., vol. 33, no. 1, 1992, pages 51 - 59, XP000617464
- [X] STRIESSNIG ET AL.: "Human red-blood-cell Ca2+-antagonist binding sites", EUR. J. BIOCHEM., vol. 150, no. 1, 1985, pages 67 - 77, XP000616619
- [A] HOELTJE ET AL.: "Qualitative and Quantitative Structure-Activity Relationship for Calcium Channel Modulating 1,4-Dihydropyridine Derivatives: A Hypothetical Molecular Receptor Model", QUANT. STRUCT. ACT. RELAT., vol. 7, no. 3, 1988, pages 174 - 178, XP000616609
- [X] PATENT ABSTRACTS OF JAPAN vol. 015, no. 252 (C - 0844) 26 June 1991 (1991-06-26)
- See references of WO 9407476A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9407476 A1 19940414; AU 5170393 A 19940426; CA 2146545 A1 19940414; EP 0663822 A1 19950726; EP 0663822 A4 19970423; JP H08502263 A 19960312

DOCDB simple family (application)

US 9309463 W 19931005; AU 5170393 A 19931005; CA 2146545 A 19931005; EP 93922832 A 19931005; JP 50938394 A 19931005